Grace Therapeutics, Inc.

GRCE · NASDAQ
Analyze with AI
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Operating Activities
Net Income-$9,568-$12,853-$42,429-$9,819
Dep. & Amort.$7$11$124$0
Deferred Tax-$3,199-$1,832-$9,542-$648
Stock-Based Comp.$730$913$1,811$1,337
Change in WC$342-$1,280$181-$2,786
Other Non-Cash-$3,216$2,708$33,942-$5,318
Operating Cash Flow-$14,904-$12,333-$15,913-$17,234
Investing Activities
PP&E Inv.$0-$22-$17$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$15-$6,554-$5,015-$34,929
Inv. Sales/Matur.$15$6,569$18,185$31,407
Other Inv. Act.$0$111$0$0
Investing Cash Flow$0$104$13,153-$3,522
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$14,999$7,500$304$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$967-$141$0$0
Financing Cash Flow$14,032$7,359$304$0
Forex Effect$0$0-$8$153
Net Chg. in Cash-$872-$4,870-$2,464-$20,603
Supplemental Information
Beg. Cash$23,005$27,875$30,339$50,942
End Cash$22,133$23,005$27,875$30,339
Free Cash Flow-$14,904-$12,355-$15,930-$17,234